Abstract:Rationale: Hypereosinophilic syndrome (HES) is a rare disorder characterized by hypereosinophilia and organ damage. Some cases of HES are caused by the FIP1L1/PDGFRA fusion gene and respond to imatinib. FIP1L1/PDGFRA-positive HES occasionally evolves into chronic eosinophilic leukemia or into another form of myeloproliferative neoplasm; however, the development of a malignant lymphoma is very rare. We present a rare case of angioimmunoblastic T-cell lymphoma (AITL) and HES with the FIP1L1/PDGFRA gene rearrangement. Patient concerns: A man in his 30s presented to our hospital with fever, hypereosinophilia, widespread lymphadenopathy, and splenomegaly. Laboratory tests showed hypereosinophilia, increased soluble interleukin-2 receptor, and increased vitamin B12. Positron-emission tomography with F fluorodeoxyglucose (FDG) showed positive FDG uptake in multiple enlarged lymph nodes throughout the body and the red bone marrow. A bone-marrow biopsy showed hypereosinophilia without dysplasia and an increased number of blasts. The FIP1L1/PDGFRA fusion gene was positive upon fluorescence in situ hybridization (FISH) analysis of the peripheral blood. Furthermore, biopsy of a lymph node from the neck revealed restiform hyperplasia of capillary vessels, with small lymphoma cells arranged around the capillaries. Lymphoma cells were positive for CD3, CD4, and CD10, and negative for CD20. Lymphoma cells were also positive for the FIP1L1/PDGFRA fusion gene by FISH analysis. Diagnoses: From these findings, the patient was diagnosed with HES and AITL with FIP1L1/PDGFRA. Interventions: After the diagnosis, corticosteroid was administered but was ineffective. Imatinib was then administered. Outcomes: Imatinib was very effective for treating HES and AITL, and complete remission was achieved in both. Lessons: This report presents the first case in which the FIP1L1/PDGFRA fusion gene was positive both in peripheral blood and lymph nodes, implying the possibility that the tumor cells acquired the FIP1L1/PDGFRA fusion gene in the early stage of hematopoietic progenitor cell developments. Imatinib was very effective in treating both HES and lymphoma, suggesting that the FIP1L1/PDGFRA fusion gene plays a key role in the pathogenesis of both HES and lymphoma.

Triptolide Abrogates Oncogene FIP1L1‐PDGFRα Addiction and Induces Apoptosis in Hypereosinophilic Syndrome

[Identification of FIP1L1-PDGFRA Fusion, and Expression of Signal Transducer and Activator of Transcription 5 in Hypereosinophilic Syndrome].

FIP1L1-PDGFRalpha Alone or with Other Genetic Abnormalities Reveals Disease Progression in Chronic Eosinophilic Leukemia but Good Response to Imatinib.

Triptolide Down-regulates Bcr-abl Expression and Induces Apoptosis in Chronic Myelogenous Leukemia Cells

Inhibition of Hsp90 by Triptolide (tpl) Augments Bortezomib-Induced U266 Cells Apoptosis

Tripterine Induces Apoptosis of Human Acute Myelocytic Leukemic Cells Via Up-Regulating Fas/FasL and Down-Regulating NF-κB

Imatinib is effective in some PDGFRA/B‐negative hypereosinophilic syndromes: A step closer to unveiling underlying mechanisms

Phase II trial of imatinib mesylate in patients with PDGFRA/B‐negative hypereosinophilic syndrome

Increased Accumulation of Hypoxia-Inducible Factor-1Α with Reduced Transcriptional Activity Mediates the Antitumor Effect of Triptolide.

Angioimmunoblastic T-cell lymphoma and hypereosinophilic syndrome with FIP1L1/PDGFRA fusion gene effectively treated with imatinib: A case report

Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70

[Targeted sequencing analysis of hyper-eosinophilic syndrome and chronic eosinophilic leukemia].

Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells

Triptolide induces apoptosis in human leukemia cells through caspase-3-mediated ROCK1 activation and MLC phosphorylation

Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-ΙΙ

Triptolide Induces Growth Inhibition And Apoptosis Of Human Laryngocarcinoma Cells By Enhancing P53 Activities And Suppressing E6-Mediated P53 Degradation

Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells

Triptolide suppresses paraquat induced idiopathic pulmonary fibrosis by inhibiting TGFB1-dependent epithelial mesenchymal transition

Triptolide Induced Cell Death Through Apoptosis and Autophagy in Murine Leukemia WEHI‐3 Cells in Vitro and Promoting Immune Responses in WEHI‐3 Generated Leukemia Mice in Vivo

Identification of a novel PDGFRA point mutation at p.P6L as a potential molecular target of imatinib in an eosinophilia patient showing genetic heterogeneity

Triptolide-induced apoptosis in p53 mutant hepatoma cells involves ROS-mutant p53- dependent inhibition effect on p21 expression